Kansas City, Mo. (July 5, 2018) – Nonprofit organizations Fight for Sight and Saving Sight have awarded a $2500 scholarship to Boston University School of Medicine student, Min Tae Kim, for his study of how type 2 diabetes effects corneal wound healing and repair. In his research, Kim will study the role of a channel protein, Pannexin-1, in both normal wound repair and that of diabetic tissue.
“With a better understanding of the wound healing process and its differences in diabetic and non-diabetic individuals, it may become possible for us to develop ways to better monitor these types of health complications and develop therapeutics targeting diabetic corneal dysfunction,” said Kim.
Kim was awarded the grant through Fight for Sight’s Summer Student Fellowship program, which provides support to undergraduate, graduate or medical students pursuing eye-related clinical or basic research. This particular scholarship was joint-funded by Kansas City area eye bank, Saving Sight.
“Saving Sight is proud to provide ongoing support to the ocular research community,” said Tony Bavuso, Chief Executive Officer at Saving Sight. “It’s exciting to contribute to the success of the next generation of ocular researchers in hopes of finding new treatments.”
About Saving Sight
Saving Sight is a 501(c)(3) nonprofit organization with a mission to change lives by saving sight. Founded in 1960, Saving Sight has grown to become one of the nation’s leading eye banks and is focused on providing innovative solutions to its clinical partners. Headquartered in Kansas City, Mo., Saving Sight facilitates eye donation in Missouri, Kansas, and Illinois, impacting the lives of those both near and far through transplantation.
About Fight for Sight
Since 1946, Fight for Sight (FFS) has supported and inspired eye and vision research by funding promising scientists early in their careers. FFS has granted over $21 million in research that has contributed directly or indirectly to major advances in ophthalmology and vision research, including the development of the IOL, aspects of donor cornea preservation, various use of ophthalmic lasers, glaucoma treatment and gene therapy.